Quick Summary Looking to gain centralised control over enterprise data assets? Explore the top 10 master data management (MDM) software solutions for enterprises in 2025 that help unify, govern, and ...

Medinex's (Catalist:OTX) stock is up by 9.1% over the past three months. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by long-term fundamentals, ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...

Orbital’s lead preclinical candidate, OTX-201, is an investigational RNA immunotherapy designed to target CD19-positive B cells involved in autoimmune diseases. The therapy is currently in ...